신성 빈혈 치료 시장 : 산업 분석, 규모, 점유율, 성장, 동향 예측(2024-2031년)

The global renal anemia treatment market, valued at approximately US$8.0 billion in 2024, is projected to grow to US$12.3 billion by 2031. The market is expected to exhibit a strong compound annual growth rate (CAGR) of 6.3% from 2024 to 2031. Here are the key highlights and trends driving the market:

Key Market Highlights:

• Market Valuation (2024): US$8.0 billion
• Projected Market Value (2031): US$12.3 billion
• CAGR (2024-2031): 6.3%

Market Drivers and Trends:

1. Rising Prevalence of Chronic Kidney Disease (CKD): The increasing global prevalence of CKD is a significant factor driving the demand for renal anemia treatments. As CKD becomes more common, the associated complication of anemia is also on the rise, fueling the need for effective treatment options.

2. Advancements in Treatment Options: Continuous advancements in renal anemia treatment, including new therapies and improved formulations, are contributing to market growth. These innovations enhance treatment efficacy and patient outcomes, driving adoption.

3. Growing Awareness of Anemia as a CKD Complication: Increased awareness of anemia as a complication of CKD is promoting early diagnosis and treatment. This awareness is driving demand for effective therapeutic solutions.

4. Investments in Research and Development: Significant investments in R&D are leading to the development of new and innovative treatments for renal anemia. These advancements are expected to expand treatment options and boost market growth.

5. Aging Global Population: The global aging population is likely to increase the incidence of renal anemia, as older adults are more prone to CKD and its complications. This demographic shift is expected to drive demand for renal anemia treatments.

Regional Insights:

1. Dominance of the US Market: The US market is expected to continue its dominance due to the early adoption of advanced treatment options and favorable reimbursement policies. High healthcare expenditure and robust healthcare infrastructure support this trend.

2. UK Market Growth: The increasing prevalence of iron deficiency anemia in the UK, coupled with innovative technologies and evolving lifestyle patterns, is anticipated to drive market growth. Additionally, the rise in per capita income and the presence of established companies contribute to increased R&D activities and product launches.

Market Challenges:

• Healthcare Costs and Access: The high cost of advanced treatments and variations in healthcare access can impact market growth. Efforts to address these challenges through improved reimbursement policies and cost-effective solutions are crucial.

Conclusion

The renal anemia treatment market is on a robust growth trajectory, driven by rising CKD prevalence, advancements in treatment, and increased awareness. Continued investments in R&D and favorable regional dynamics are expected to further propel market expansion.

Key Companies Profiled:

• Johnson & Johnson
• Roche Holding AG
• Fresenius Medical Care AG & Co. KGaA
• Pharmacosmos A/S
• Vifor Pharma Group
• Kyowa Kirin Co., Ltd.
• Rockwell Medical, Inc.
• Akebia Therapeutics, Inc.
• AMAG Pharmaceuticals, Inc.

Renal Anemia Treatment Industry Segmentation

By Treatment

• Medications
• Dietary Supplements

By Disease

• Normocytic anemia
• Microcytic anemia
• Macrocytic anemia

By Distribution Channel

• Institutional Pharmacies
• Retail Pharmacies
• Mail Order Pharmacies

By Region

• North America
• Europe
• Asia Pacific
• Middle East
• Oceania
• Africa

Table of Contents

1. Executive Summary

• 1.1. Global Renal Anemia Treatment Market Snapshot, 2024-2031
• 1.2. Market Opportunity Assessment, 2024-2031, US$ Bn
• 1.3. Key Market Trends
• 1.4. Future Market Projections
• 1.5. Premium Market Insights
• 1.6. Industry Developments and Key Market Events
• 1.7. PMR Analysis and Recommendations

2. Market Overview

• 2.1. Market Scope and Definition
• 2.2. Market Dynamics
  • 2.2.1. Drivers
  • 2.2.2. Restraints
  • 2.2.3. Opportunity
  • 2.2.4. Challenges
  • 2.2.5. Key Trends
• 2.3. Macro-Economic Factors
  • 2.3.1. Global Sectorial Outlook
  • 2.3.2. Global GDP Growth Outlook
  • 2.3.3. Global Healthcare Spending Outlook
• 2.4. COVID-19 Impact Analysis
• 2.5. Forecast Factors - Relevance and Impact

3. Value Added Insights

• 3.1. Epidemiology - Disease Prevalence and Incidence
• 3.2. Technology Assessment
• 3.3. Regulatory Landscape
• 3.4. Value Chain Analysis
• 3.5. Key Deals and Mergers
• 3.6. PESTLE Analysis
• 3.7. Porter's Five Force Analysis

4. Global Renal Anemia Treatment Market Outlook: Historical (2019-2023) and Forecast (2024-2031)

• 4.1. Key Highlights
  • 4.1.1. Market Size (US$ Bn) and Y-o-Y Growth
  • 4.1.2. Absolute $ Opportunity
• 4.2. Market Size (US$ Bn) Analysis and Forecast
  • 4.2.1. Historical Market Size (US$ Bn) Analysis, 2019-2023
  • 4.2.2. Current Market Size (US$ Bn) Analysis and Forecast, 2023-2031
• 4.3. Global Renal Anemia Treatment Market Outlook: Treatment
  • 4.3.1. Introduction / Key Findings
  • 4.3.2. Historical Market Size (US$ Bn) Analysis, By Treatment, 2019-2023
  • 4.3.3. Current Market Size (US$ Bn) Analysis and Forecast, By Treatment, 2024-2031
    • 4.3.3.1. Medications
    • 4.3.3.2. Dietary Supplements
• 4.4. Market Attractiveness Analysis: Treatment
• 4.5. Global Renal Anemia Treatment Market Outlook: Disease
  • 4.5.1. Introduction / Key Findings
  • 4.5.2. Historical Market Size (US$ Bn) Analysis, By Disease, 2019-2023
  • 4.5.3. Current Market Size (US$ Bn) Analysis and Forecast, By Disease, 2024-2031
    • 4.5.3.1. Normocytic anemia
    • 4.5.3.2. Microcytic anemia
    • 4.5.3.3. Macrocytic anemia
• 4.6. Market Attractiveness Analysis: Disease
• 4.7. Global Renal Anemia Treatment Market Outlook: Distribution Channel
  • 4.7.1. Introduction / Key Findings
  • 4.7.2. Historical Market Size (US$ Bn) Analysis, By Distribution Channel, 2019-2023
  • 4.7.3. Current Market Size (US$ Bn) Analysis and Forecast, By Distribution Channel, 2024-2031
    • 4.7.3.1. Normocytic anemia
    • 4.7.3.2. Microcytic anemia
    • 4.7.3.3. Macrocytic anemia
• 4.8. Market Attractiveness Analysis: Distribution Channel

5. Global Renal Anemia Treatment Market Outlook: Region

• 5.1. Key Highlights
• 5.2. Historical Market Size (US$ Bn) Analysis, By Region, 2019-2023
• 5.3. Current Market Size (US$ Bn) Analysis and Forecast, By Region, 2024-2031
  • 5.3.1. North America
  • 5.3.2. Europe
  • 5.3.3. East Asia
  • 5.3.4. South Asia and Oceania
  • 5.3.5. Latin America
  • 5.3.6. Middle East & Africa
• 5.4. Market Attractiveness Analysis: Region

6. North America Renal Anemia Treatment Market Outlook: Historical (2019-2023) and Forecast (2024-2031)

• 6.1. Key Highlights
• 6.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2023
  • 6.2.1. By Country
  • 6.2.2. By Treatment
  • 6.2.3. By Disease
  • 6.2.4. By Distribution Channel
• 6.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2024-2031
  • 6.3.1. U.S.
  • 6.3.2. Canada
• 6.4. Current Market Size (US$ Bn) Analysis and Forecast, By Treatment, 2024-2031
  • 6.4.1. Medications
  • 6.4.2. Dietary Supplements
• 6.5. Current Market Size (US$ Bn) Analysis and Forecast, By Disease, 2024-2031
  • 6.5.1. Normocytic anemia
  • 6.5.2. Microcytic anemia
  • 6.5.3. Macrocytic anemia
• 6.6. Current Market Size (US$ Bn) Analysis and Forecast, By Distribution Channel, 2024-2031
  • 6.6.1. Institutional Pharmacies
  • 6.6.2. Retail Pharmacies
  • 6.6.3. Mail Order Pharmacies
• 6.7. Market Attractiveness Analysis

7. Europe Renal Anemia Treatment Market Outlook: Historical (2019-2023) and Forecast (2024-2031)

• 7.1. Key Highlights
• 7.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2023
  • 7.2.1. By Country
  • 7.2.2. By Treatment
  • 7.2.3. By Disease
  • 7.2.4. By Distribution Channel
• 7.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2024-2031
  • 7.3.1. Germany
  • 7.3.2. France
  • 7.3.3. U.K.
  • 7.3.4. Italy
  • 7.3.5. Spain
  • 7.3.6. Russia
  • 7.3.7. Turkey
  • 7.3.8. Rest of Europe
• 7.4. Current Market Size (US$ Bn) Analysis and Forecast, By Treatment, 2024-2031
  • 7.4.1. Medications
  • 7.4.2. Dietary Supplements
• 7.5. Current Market Size (US$ Bn) Analysis and Forecast, By Disease, 2024-2031
  • 7.5.1. Normocytic anemia
  • 7.5.2. Microcytic anemia
  • 7.5.3. Macrocytic anemia
• 7.6. Current Market Size (US$ Bn) Analysis and Forecast, By Distribution Channel, 2024-2031
  • 7.6.1. Institutional Pharmacies
  • 7.6.2. Retail Pharmacies
  • 7.6.3. Mail Order Pharmacies
• 7.7. Market Attractiveness Analysis

8. East Asia Renal Anemia Treatment Market Outlook: Historical (2019-2023) and Forecast (2024-2031)

• 8.1. Key Highlights
• 8.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2023
  • 8.2.1. By Country
  • 8.2.2. By Treatment
  • 8.2.3. By Disease
  • 8.2.4. By Distribution Channel
• 8.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2024-2031
  • 8.3.1. China
  • 8.3.2. Japan
  • 8.3.3. South Korea
• 8.4. Current Market Size (US$ Bn) Analysis and Forecast, By Treatment, 2024-2031
  • 8.4.1. Medications
  • 8.4.2. Dietary Supplements
• 8.5. Current Market Size (US$ Bn) Analysis and Forecast, By Disease, 2024-2031
  • 8.5.1. Normocytic anemia
  • 8.5.2. Microcytic anemia
  • 8.5.3. Macrocytic anemia
• 8.6. Current Market Size (US$ Bn) Analysis and Forecast, By Distribution Channel, 2024-2031
  • 8.6.1. Institutional Pharmacies
  • 8.6.2. Retail Pharmacies
  • 8.6.3. Mail Order Pharmacies
• 8.7. Market Attractiveness Analysis

9. South Asia & Oceania Renal Anemia Treatment Market Outlook: Historical (2019-2023) and Forecast (2024-2031)

• 9.1. Key Highlights
• 9.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2023
  • 9.2.1. By Country
  • 9.2.2. By Treatment
  • 9.2.3. By Disease
  • 9.2.4. By Distribution Channel
• 9.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2024-2031
  • 9.3.1. India
  • 9.3.2. Southeast Asia
  • 9.3.3. ANZ
  • 9.3.4. Rest of South Asia & Oceania
• 9.4. Current Market Size (US$ Bn) Analysis and Forecast, By Treatment, 2024-2031
  • 9.4.1. Medications
  • 9.4.2. Dietary Supplements
• 9.5. Current Market Size (US$ Bn) Analysis and Forecast, By Disease, 2024-2031
  • 9.5.1. Normocytic anemia
  • 9.5.2. Microcytic anemia
  • 9.5.3. Macrocytic anemia
• 9.6. Current Market Size (US$ Bn) Analysis and Forecast, By Distribution Channel, 2024-2031
  • 9.6.1. Institutional Pharmacies
  • 9.6.2. Retail Pharmacies
  • 9.6.3. Mail Order Pharmacies
• 9.7. Market Attractiveness Analysis

10. Latin America Renal Anemia Treatment Market Outlook: Historical (2019-2023) and Forecast (2024-2031)

• 10.1. Key Highlights
• 10.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2023
  • 10.2.1. By Country
  • 10.2.2. By Treatment
  • 10.2.3. By Disease
  • 10.2.4. By Distribution Channel
• 10.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2024-2031
  • 10.3.1. Brazil
  • 10.3.2. Mexico
  • 10.3.3. Rest of Latin America
• 10.4. Current Market Size (US$ Bn) Analysis and Forecast, By Treatment, 2024-2031
  • 10.4.1. Medications
  • 10.4.2. Dietary Supplements
• 10.5. Current Market Size (US$ Bn) Analysis and Forecast, By Disease, 2024-2031
  • 10.5.1. Normocytic anemia
  • 10.5.2. Microcytic anemia
  • 10.5.3. Macrocytic anemia
• 10.6. Current Market Size (US$ Bn) Analysis and Forecast, By Distribution Channel, 2024-2031
  • 10.6.1. Institutional Pharmacies
  • 10.6.2. Retail Pharmacies
  • 10.6.3. Mail Order Pharmacies
• 10.7. Market Attractiveness Analysis

11. Middle East & Africa Renal Anemia Treatment Market Outlook: Historical (2019-2023) and Forecast (2024-2031)

• 11.1. Key Highlights
• 11.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2023
  • 11.2.1. By Country
  • 11.2.2. By Treatment
  • 11.2.3. By Disease
  • 11.2.4. By Distribution Channel
• 11.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2024-2031
  • 11.3.1. GCC Countries
  • 11.3.2. Egypt
  • 11.3.3. South Africa
  • 11.3.4. Northern Africa
  • 11.3.5. Rest of Middle East & Africa
• 11.4. Current Market Size (US$ Bn) Analysis and Forecast, By Treatment, 2024-2031
  • 11.4.1. Medications
  • 11.4.2. Dietary Supplements
• 11.5. Current Market Size (US$ Bn) Analysis and Forecast, By Disease, 2024-2031
  • 11.5.1. Normocytic anemia
  • 11.5.2. Microcytic anemia
  • 11.5.3. Macrocytic anemia
• 11.6. Current Market Size (US$ Bn) Analysis and Forecast, By Distribution Channel, 2024-2031
  • 11.6.1. Institutional Pharmacies
  • 11.6.2. Retail Pharmacies
  • 11.6.3. Mail Order Pharmacies
• 11.7. Market Attractiveness Analysis

12. Competition Landscape

• 12.1. Market Share Analysis, 2023
• 12.2. Market Structure
  • 12.2.1. Competition Intensity Mapping By Market
  • 12.2.2. Competition Dashboard
• 12.3. Company Profiles (Details - Overview, Financials, Strategy, Recent Developments)
  • 12.3.1. Amgen Inc.
    • 12.3.1.1. Overview
    • 12.3.1.2. Segments and Products
    • 12.3.1.3. Key Financials
    • 12.3.1.4. Market Developments
    • 12.3.1.5. Market Strategy
  • 12.3.2. Johnson & Johnson
  • 12.3.3. Roche Holding AG
  • 12.3.4. Fresenius Medical Care AG & Co. KGaA
  • 12.3.5. Pharmacosmos A/S
  • 12.3.6. Vifor Pharma Group
  • 12.3.7. Kyowa Kirin Co., Ltd.
  • 12.3.8. Rockwell Medical, Inc.
  • 12.3.9. Akebia Therapeutics, Inc.
  • 12.3.10. AMAG Pharmaceuticals, Inc.

13. Appendix

• 13.1. Research Methodology
• 13.2. Research Assumptions
• 13.3. Acronyms and Abbreviations